Viatris' India Facility Receives Warning Letter and Import Alert From US FDA

MT Newswires Live12-24

Viatris (VTRS) said Monday that the US Food and Drug Administration has issued a warning letter and an import alert to its oral finished dose manufacturing facility in India, following an inspection earlier this year.

The import alert impacts 11 products, which will not be accepted in the US until the FDA lifts the warning letter, Viatris said.

Viatris said it has implemented a "comprehensive" remediation plan, including corrective and preventive actions, and continues to work with the FDA to address the issues raised.

The company does not anticipate these actions will affect its 2024 financial guidance and plans to update its 2025 financial guidance accordingly, Viatris said.

Viatris shares fell 0.6% in recent trading.

Price: 12.44, Change: -0.08, Percent Change: -0.62

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493767465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-24 00:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493767465","market":"hk","top_or_hot":-1,"title":"Viatris' India Facility Receives Warning Letter and Import Alert From US FDA","media":"MT Newswires Live","content":"<html><body><p> Viatris (VTRS) said Monday that the US Food and Drug Administration has issued a warning letter and an import alert to its oral finished dose manufacturing facility in India, following an inspection earlier this year.</p><p>The import alert impacts 11 products, which will not be accepted in the US until the FDA lifts the warning letter, Viatris said.</p><p>Viatris said it has implemented a \"comprehensive\" remediation plan, including corrective and preventive actions, and continues to work with the FDA to address the issues raised.</p><p>The company does not anticipate these actions will affect its 2024 financial guidance and plans to update its 2025 financial guidance accordingly, Viatris said.</p><p>Viatris shares fell 0.6% in recent trading.</p><p>Price: 12.44, Change: -0.08, Percent Change: -0.62</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viatris' India Facility Receives Warning Letter and Import Alert From US FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViatris' India Facility Receives Warning Letter and Import Alert From US FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-24 00:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Viatris (VTRS) said Monday that the US Food and Drug Administration has issued a warning letter and an import alert to its oral finished dose manufacturing facility in India, following an inspection ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493767465","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493767465","pubTimestamp":1734970657,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Viatris  said Monday that the US Food and Drug Administration has issued a warning letter and an import alert to its oral finished dose manufacturing facility in India, following an inspection earlier this year.The import alert impacts 11 products, which will not be accepted in the US until the FDA lifts the warning letter, Viatris said.Viatris said it has implemented a \"comprehensive\" remediation plan, including corrective and preventive actions, and continues to work with the FDA to address the issues raised.The company does not anticipate these actions will affect its 2024 financial guidance and plans to update its 2025 financial guidance accordingly, Viatris said.Viatris shares fell 0.6% in recent trading.Price: 12.44, Change: -0.08, Percent Change: -0.62","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4583":"猴痘概念","BK4007":"制药","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","VTRS":"Viatris Inc."},"translate_title":"Viatris印度工厂收到美国FDA的警告信和进口警报","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":0.9},"content_text":"Viatris (VTRS) said Monday that the US Food and Drug Administration has issued a warning letter and an import alert to its oral finished dose manufacturing facility in India, following an inspection earlier this year.The import alert impacts 11 products, which will not be accepted in the US until the FDA lifts the warning letter, Viatris said.Viatris said it has implemented a \"comprehensive\" remediation plan, including corrective and preventive actions, and continues to work with the FDA to address the issues raised.The company does not anticipate these actions will affect its 2024 financial guidance and plans to update its 2025 financial guidance accordingly, Viatris said.Viatris shares fell 0.6% in recent trading.Price: 12.44, Change: -0.08, Percent Change: -0.62","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493767465"}